Headlands Technologies’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
VCM
VPM
Headlands Technologies's DNLI Position: Q1 2026 in Review
Headlands Technologies reduced its Denali Therapeutics (DNLI) stake by 77% in Q1 2026, selling an estimated $713K and leaving 10,557 shares worth $203K. The position accounts for 0.02% of the portfolio, ranked #594.
Headlands Technologies first reported a position in DNLI in Q1 2024 and has held it in 4 quarters since. The position peaked at $766K in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Headlands Technologies held 10,557 shares of Denali Therapeutics worth $203K as of Q1 2026.
- Headlands Technologies sold 35,826 Denali Therapeutics shares in Q1 2026, an estimated $713K.
- Denali Therapeutics made up 0.02% of Headlands Technologies's portfolio in Q1 2026, its #594 holding.
- Headlands Technologies first reported a position in Denali Therapeutics in Q1 2024 and has held it in 4 quarters since.
- Headlands Technologies's Denali Therapeutics position peaked at $766K in Q4 2025.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.